Figure legends
Figure 1: Biologic outcomes for Omalizumab and Mepolizumab at the
end-of-trial. ACQ6: Asthma Control Questionnaire 6. AHE: acute
healthcare encounters, which include Emergency department/ hospital
admissions. OCS: oral corticosteroids. mg: milligrams.
FEV1: forced expiratory volume in one second. AQLQ:
Asthma Quality of Life Questionnaire. HADS: Hospital anxiety and
depression scale.
Figure 2: Alternative assessments of biologic outcomes. Figure 2a:
Side-by-side comparisons of different measures of biologic response.
Figure 2b: Mepolizumab focused measures of biologic response. Numbers
represent patient counts. ACQ: Asthma Control Questionnaire 6. AHE:
acute healthcare encounters, which include Emergency department/
hospital admissions. OCS: Response with regard to exacerbations
(incidence of exacerbations needing an acute OCS course or an increase
in maintenance OCS dose). AQLQ: Asthma Quality of Life Questionnaire.
MDT: multi-disciplinary team decision. Response for ACQ and AQLQ was
defined as a reduction greater than the minimally important difference
of ≥0.5. AHE response was defined as patients who had ≥1 AHE at baseline
but now currently have no AHE. OCS response is defined as a reduction of
maintenance OCS dose or exacerbations by ≥50%. MDT response is defined
earlier in the methods. The blue outlier in figure 2a and 2b is a
patient who reduced his maintenance OCS from 10-7mg and had no
exacerbations nor AHE in the trial period (from a baseline of 0), and
thereby had a positive trial.